Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMaría Teresa Cedena RomeroEOEnrique M. OcioYGYolanda González‐Montes

Discussion

Loading...

Member takes

Overview

Investigation reveals minimally invasive monitoring of residual disease improves progression-free survival in myeloma, suggesting enhanced treatment strategies.

Key Points

  • Among 247 patients with monitoring, those with detectable circulating tumor cells had a median progression-free survival of 3 months.
  • The study utilized mass spectrometry and blood flow monitoring to assess residual disease in bone marrow and serum.
  • Dynamic monitoring of residual disease indicated a high independent prognostic value for identifying patients at risk of disease progression.
  • Results showed that detecting circulating tumor cells significantly increased the risk of progression and reduced survival outcomes.

Cite This Study

Romero et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc89https://doi.org/10.1182/blood-2025-919
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study2025
  2. 2Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  3. 3Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 2 citations
  4. 4Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  5. 5Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025